[HTML][HTML] Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis

G Meng, X Liu, T Ma, D Lv, G Sun - PLoS One, 2022 - journals.plos.org
Background Immunotherapy has emerged as a promising treatment for non-small cell lung
cancer (NSCLC). Yet, some patients cannot benefit from immunotherapy, and reliable …

[HTML][HTML] Heat Shock Proteins and Breast Cancer

M Zhang, X Bi - International Journal of Molecular Sciences, 2024 - mdpi.com
Heat shock proteins (Hsps) are a group of stress-induced proteins involved in protein folding
and maturation. Based on their molecular weight, Hsps can be divided into six families …

[HTML][HTML] PD-L1 expression by RNA-sequencing in non-small cell lung cancer: concordance with immunohistochemistry and associations with pembrolizumab …

MK Nesline, RA Previs, GK Dy, L Deng, YH Lee… - Cancers, 2023 - mdpi.com
Simple Summary We compared RNA next-generation sequencing (RNA-seq) to standard
immunohistochemistry (IHC) for PD-L1 expression measurement and associations with …

[HTML][HTML] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma

LC Brown, J Zhu, K Desai, E Kinsey, C Kao… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immunotherapy combinations including ipilimumab and nivolumab are now the
standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of …

[HTML][HTML] RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers

E Severson, BR Achyut, M Nesline, S Pabla… - The Journal of Molecular …, 2023 - Elsevier
NRG1 gene fusions are rare, therapeutically relevant, oncogenic drivers that occur across
solid tumor types. To understand the landscape of NRG1 gene fusions, 4397 solid tumor …

The latest developments in biomarkers predicting response to immunotherapy

G Roviello, M Bersanelli, M Catalano - Immunotherapy, 2022 - Taylor & Francis
Full article: The Latest Developments in Biomarkers Predicting Response to Immunotherapy
Skip to Main Content Taylor and Francis Online homepage Taylor and Francis Online …

[HTML][HTML] Visceral obesity in non-small cell lung cancer

L Nitsche, Y Vedire, E Kannisto, X Wang, RJ Seager… - Cancers, 2022 - mdpi.com
Simple Summary Body mass index may be an inappropriate metric for obesity in lung cancer
as its use obscures the harm that obesity causes, which is noticeable when obesity is …

Real-world comprehensive genomic and immune profiling reveals distinct age-and sex-based genomic and immune landscapes in tumors of patients with non-small …

ZD Wallen, H Ko, MK Nesline, SB Hastings… - Frontiers in …, 2024 - frontiersin.org
Introduction Younger patients with non-small cell lung cancer (NSCLC)(< 50 years)
represent a significant patient population with distinct clinicopathological features and …

[HTML][HTML] Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer

RJ Seager, MF Senosain, E Van Roey, S Gao… - Journal of Translational …, 2024 - Springer
Abstract Background Cancer-testis antigens (CTAs) are tumor antigens that are normally
expressed in the testes but are aberrantly expressed in several cancers. CTA …

[HTML][HTML] Dual Oxidase 2 (DUOX2) as a Proteomic Biomarker for Predicting Treatment Response to Chemoradiation Therapy for Locally Advanced Rectal Cancer …

H Lee, HS Ryu, HC Park, JI Yu, GS Yoo, C Choi… - International Journal of …, 2022 - mdpi.com
High-throughput mass-spectrometry-based quantitative proteomic analysis was performed
using formalin-fixed, paraffin-embedded (FFPE) biopsy samples obtained before treatment …